We are approaching the end of 2025, a year of remarkable breakthroughs in medicine, technology, and lifestyle. From AI ...
News-Medical.Net on MSN
New framework tracks response to anti-amyloid therapies in Alzheimer's
In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...
MedPage Today on MSN
Alzheimer's Benefits May Continue After Donanemab Treatment Ends, Data Suggest
Early Alzheimer's patients who completed their course of donanemab therapy by 12 months had cognitive and functional benefits lasting for 2 additional years, reported Jennifer Zimmer, MD, of Eli Lilly ...
A dog owner has praised a Dorset veterinary practice for saving her pet’s life by removing a tumour “the size of a newborn ...
Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...
In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called ...
News-Medical.Net on MSN
Metabolic imaging enables early response prediction in bone-dominant metastatic breast cancer
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...
The drug was approved for use in the United States two years ago, and 50 other countries have followed suit. It’s the first ...
A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...
Experts concluded the drug, which slows the progression of the disease for some people, did not have therapeutic value ...
An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring ...
An expanding market – along with a CMA review – should mean a fairer deal for pet owners. But providers must also be ready to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback